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266 The Journal of Thoracic and Cardbjective: Pneumonectomy is not always sufficient for the radical resection of
ancer. In the present study, pneumonectomy may be associated with an extended
esection of mediastinal or parietal structures. The postoperative risk and the
ncologic benefits of such an extended procedure have not been sufficiently dem-
nstrated.
ethods: We have defined “extended” pneumonectomy (EP) as the removal of the
ntire lung, associated with one or more of the following structures: superior vena
ava, tracheal carina, left atrium, aorta, chest wall, or diaphragm. Our clinical
atabase was retrospectively reviewed to identify patients who underwent EP to
ssess their postoperative morbidity, mortality, and long-term survival.
esults: Between 1998 and 2005, 47 EPs were performed. The “extended” proce-
ure included left atrium resection in 15 patients, combined SVC and carinal
esection in 9 patients, aortic resection in 8 patients (in 3 patients with prosthetic
eplacement), chest wall or diaphragmatic resection in 6 patients, SVC resection in
patients, and carinal resection in 4 patients. A partial esophageal muscular
esection was performed in 1 patient. Overall 60-day mortality was 8.5%. Major
ostoperative complications occurred in 8 patients (17%). The 2- and 5-year
urvival rates for the overall population were 42% and 22.8%, respectively. Inter-
stingly, long-term survivors were recorded only in the group of patients who
eceived induction treatment.
onclusions: Extended pneumonectomy is a feasible procedure with an acceptable
isk factor. To improve the selection of patients, all candidates should undergo
reoperative mediastinoscopy and induction chemotherapy. In patients with positive
esponse to chemotherapy or stable disease, extended pneumonectomy may afford
radical resection in more than 80% of cases and may result in a permanent cure
n some instances.
omplete tumor removal is the objective of any surgical resection when
treating lung cancer.1 A tumor may infiltrate contiguous structures such
as the superior vena cava (SVC), tracheal carina, left atrium, diaphragm,
r chest wall. It has been demonstrated that in all of these situations, a radical
esection can be achieved by combining an “extended” procedure such as SVC
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G
TSrosthetic replacement, tracheal “sleeve,” or left atrium
esection with lung surgery, resulting in acceptable mor-
idity and mortality rates as well as satisfactory long-
erm results.2-5
Of all anatomic resections, pneumonectomy is associated
ith the highest postoperative mortality rate,6,7 particularly
fter induction treatment,8 and it is often considered a cause
f illness in itself, because of its adverse impact on the
uality of life of long-term patients. When both an extended
rocedure and pneumonectomy are required to radically
esect a tumor, surgical risk increases and the certainty of
ncologic benefits diminishes.
To clarify the role of the extended pneumonectomy in
he management of lung cancer patients, we reviewed our
atient data (a) to assess the additional risk of extended
neumonectomy as compared with that of standard pneu-
onectomy in terms of postoperative morbidity and mor-
ality, and (b) to evaluate long-term survival after such an
nvasive approach.
aterials and Methods
e have defined “extended” pneumonectomy as the removal of
he entire lung associated with one or more of the following
tructures: superior vena cava (SVC), tracheal carina, left atrium,
orta, chest wall, and diaphragm.
The clinical database of the Thoracic Surgery Department of
he European Institute of Oncology was reviewed to identify
atients who underwent extended pneumonectomy between Janu-
ry 1998 and March 2005. Our Ethical Committee was informed of
he study and did not require approval. All patients gave their
nformed consent for the study.
reoperative Management
reoperative work-up consisted of brain, chest, and upper abdo-
en enhanced CT scan, and bronchoscopic scan. From 2000 on,
ositron emission tomography was routinely used. Functional
valuation was performed by spirometry, blood gas analysis, and
ung perfusion scan. A predicted postoperative FEV1 value of less
han 30% was considered a contraindication to pneumonectomy.
Patients having one or more mediastinal lymph nodes with a
iameter larger than 1 cm in their short axis on CT scan underwent
ediastinoscopy. When N2 disease was detected, they underwent
nduction chemotherapy in three cycles of cisplatin and gemcitab-
ne (cisplatinum 80 mg/m2 days 1,21 and gemcitabine 1250 mg/m2
Abbreviations and Acronyms
ALI  acute lung injury
ARDS  acute respiratory distress syndrome
EP  “extended” pneumonectomy
NSCLC non–small cell lung cancer
SVC  superior vena cava
VATS  video-assisted thoracoscopic surgeryays 1,8,21) and, in the case of tumor reduction or stable disease, l
The Journal of Thoracichey underwent surgery. In patients without mediastinal involve-
ent, induction chemotherapy was discussed case by case. The
resence of pleural effusion or the clinical suspicion of pleural
isease was investigated by video-assisted thoracoscopy in all
ases.
Restaging after chemotherapy was performed by brain, chest,
nd upper abdomen enhanced CT scan and bronchoscopy. The
nal decision on indication for surgery was taken after multidis-
iplinary discussion. The delay between the end of chemotherapy
nd surgery was 4 to 5 weeks.
ostoperative Complications
ostoperative death was defined as any death occurring during
ospital stay, or within 30 days after surgery. Sixty-day death was
efined as any death occurring within two months from the day of
neumonectomy.
Postoperative complications were classified as: (1) respiratory
acute respiratory failure, ARDS and ALI, as defined by the
merican European Consensus Conference on ARDS in 1994,9
neumonia, sputum retention, pulmonary embolism, pulmonary
edema, chronic respiratory failure), (2) cardiac (cardiac arryth-
ia, angina, myocardial infarction, cardiogenic shock), (3) surgi-
al (SVC thrombosis, hemothorax, bronchial fistula, empyema,
hylothorax, cardiac dislocation), and (4) others. Respiratory, sur-
ical, and cardiac events with the exception of cardiac arrythmia
ere considered to be major complications. All the others were
efined as minor complications.
ntraoperative Management
ntraoperative management was focused on reducing the risk of
amage to the controlateral lung; fluid administration was in the
rder of 5–7ml/kg/hour cristalloids infusion, not exceeding a total
mount of 1500 ml in all cases.
In patients requiring SVC resection, intraoperative fluids and
asoactive agents administration was managed differently until
VC replacement was completed. The objective was to obtain a
ean arterial pressure before clamping of 80 mmHg, to compen-
ate for the expected drop in arterial pressure at SVC clamping,
ue to the reduction in cardiac output.10
Ventilation was managed using a protective-ventilation strat-
gy (a tidal volume  6ml/kg, driving pressure  20 cm H20
bove the PEEP value, permissive hypercapnia, and the preferen-
ial use of pressure-limited ventilatory modes).11
The bronchial stump was covered in all cases. Because ex-
ended pneumonectomy is often performed intrapericardially, the
vailabilty of autologous pericardium is often limited and for this
eason it was rarely used. The preference was to cover the stump
sing a pedicled mediastinal fat pad. When it was not available, a
edicled parietal pleura flap was used.
tatistical Analysis
he impact of the following 10 variables on postoperative mor-
idity was verified (age, sex, induction treatment, preoperative
EV1%, side of pneumonectomy, carinal reconstruction, SVC
esection, atrial resection, chest wall resection, and diaphragmatic
esection).
Patients were divided into two groups based on the presence or
ack of major postoperative complications and were compared for
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G
TSll relevant variables using frequency tables for categorical vari-
bles and summary statistics for continuous variables. Chi-square
r Fisher’s exact test were applied when appropriate.
Postoperative complications were considered as outcome vari-
bles in a logistic regression model, using the defined covariates.
he Odds-ratio and a corresponding 95% of CIs were reported for
ovariates considered clinically relevant or statistically significant
t the 0.05 significance level (Wald chi-square test) and then
ncluded in the final multivariate model.
Overall survival and disease-free intervals were estimated from
he date of surgery using the Kaplan–Meier survival analysis
ethod. Survival comparisons by stage were analyzed by log–rank
est; the difference was considered statistically significant when
-value was less than 0.05.
Follow-up information was obtained via telephone contact on
ctober 2005.
esults
uring the period of the present study, 269 pneumonecto-
ies were performed. Forty-seven of them (39 males, mean
ge 58.6 years) underwent extended pneumonectomies for
ung cancer representing the population of the study. Patient
haracteristics are listed in Table 1.
Thirty-eight patients received preoperative induction
hemotherapy. Of the extended procedures associated with
neumonectomy, 15 patients underwent atrium resection (in
ne patient, this procedure was combined with aortic resec-
ion), 9 patients underwent combined SVC and carinal re-
ection, 8 patients underwent aortic resection (in 3 patients
ith prosthetic replacement, in 1 patient with direct repair,




reoperative chemotherapy 38 80.8
reoperative FEV1%  50% 2 4.2
athologic condition
Squamous cell carcinoma 29 61.7
Adenocarcinoma 12 25.5
Large-cell carcinoma 2 4.2
esection associated with pneumonectomy
Left atrium resection 15 32
Superior vena cava resection 13 27.6
Carinal resection 13 27.6
SVC  carinal resection 9 19.1
Aorta resection 8 17
athologic stage
Stage I 1 2.1
Stage II 3 6.4
Stage III 43 91.4
athologic T 4 17 36.2
athologic T4 30 63.8n 4 patients by subadventitial resection), 6 patients under- t
268 The Journal of Thoracic and Cardiovascular Surgery ● Novent chest wall or diaphragmatic resection (with another
xtended resection in 2 patients), with 4 patients having
VC resection, 4 patients having carina resection, and 1
atient having partial esophageal muscular resection.
After surgery, postoperative complications occurred in
7 patients (57.4%). Major complications occurred in 8
atients (17%), most of them surgical: 3 early bronchopleu-
al fistulas, 2 hemothoraces, and 1 cardiac herniation, due to
ericardial prosthesis rupture. Five major respiratory com-
lications were recorded (10.6%): respiratory failure in 3
ases, ARDS in 1 case, and pulmonary embolism in 1 case.
our patients required temporary tracheostomy for pro-
onged mechanical ventilation. Univariate analysis did not
dentify any risk factor for the occurrence of major postop-
rative complications.
Two postoperative deaths were recorded (overall mortal-
ty rate 4.2%) because of ARDS after re-thoracotomy for
stula in one case and simultaneous pulmonary embolism
nd tracheobronchial fistula in the other. The average ICU
as 3 days (range 0–42), with the average hospital stay 10
ays (range 5–60). Two subsequent deaths were recorded
fter discharge, within the 60-day margin: in 1 patient death
as due to cardiac failure after left atrium resection, and in
patient sudden death occurred at home, with the cause
emaining unclear.
A radical resection was obtained in 87% of cases. Final
athologic details are given in Table 1.
Complete follow-up was achieved in all but one patient.
7% of patients were still alive (22/47) at the mean follow-up
ime of 19 months. Eighteen (38%) were disease free, whereas
our had experienced relapse. Out of the 25 recorded deaths, 14
ere due to recurrent disease and 11 due to causes unrelated to
ancer. In 1 case, the information was not available. Apart
rom the 4 patients who died within 60 days of surgery, 4
atients died because of respiratory causes, 1 of cardiac causes,
of sudden death.
The 2-year and 5-year survival rates for the overall
opulation were 42% and 22.8%, respectively. The overall
edian survival time was 22 months (95% CI 18–36).
Regardless of the negligible statistical significance, two
ariables seem to affect long-term survival: lymph node status
nd type of extended resection. Patients who had mediastinal
odal metastases (N2) had a lower 5-year survival rate (41.2%)
ompared with those without mediastinal involvement (8.1%,
 0.13, figure 1). Moreover, patients who underwent carinal
esection had a better prognosis as compared with that of those
ho underwent left atrial resection (34% and 17%, respec-
ively, p  0.05). Pathologic T status did not affect long-term
urvival (22% and 26%, respectively, at 5 years for pT 4 and
T4 tumors, p  0.5).
It may be interesting to note that long-term survival was
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TSiscussion
ung cancer requiring an “extended” pneumonectomy rep-
esents one of the most challenging surgical interventions in
ncology, for several reasons.
First, when dealing with patients with suspected medi-
stinal infiltration, staging of the tumor is extremely diffi-
ult because of radiologic inaccuracy.12,13 This inaccuracy
an potentially translate into over-treatment in the cases of
VC, atrial, or carinal resection in “false T4” patients (pa-
ients with clinical T4 disease that is not confirmed by
athologic testing), which in our series was in the order of
5%. Moreover, the majority of these patients received
hemotherapy before surgery, making the distinction be-
ween the response to chemotherapy and an erroneous tu-
or staging even more problematic.
Second, surgeons who consider clinical T4 tumors as
noperable by definition probably deny permanent cure to a
ertain proportion of patients. This attitude is not com-
letely justified, given the fact that a T4 tumor can some-
imes be radically removed by a tangential SVC14 or a
artial left atrium resection,15 two procedures that do not
ncrease morbidity and that should be in the repertoire of
Figure 1. Patients who had mediastinal nodal metastas
of those without mediastinal involvement (N0 and N1,very thoracic surgeon. e
The Journal of ThoracicThe disadvantage of surgical exploration in clinical T4
atients is that the rate of exploratory thoracotomy is higher.
uring the study period, we performed 5 exploratory thoracot-
mies in cT4 patients, mainly due to infiltration of the aortic
rch (4 cases), which means unresectable disease in almost
0% of cases. A more extensive use of VATS as a staging tool
ould probably reduce the rate of exploration in case of sus-
ected aortic infiltration. Morbidity of exploratory thoracot-
my when the tumor infiltrates the mediastinum is significant
60% in our experience), because operability can be diagnosed
nly after extended dissection and intrapericardial vessels iso-
ation. In tumors infiltrating both SVC and the carina, the final
udgment on the airways is possible only after SVC resection.
This type of surgery requires highly specialized centers,
killed surgeons, and skilled anesthesists, given the com-
lexity of intraoperative and postoperative management.
or example, pneumonectomy requires intraoperative fluid
estriction, whereas, at the same time, SVC crossclamping
equires generous fluid administration in order to overcome
rterial tension drop and the risk of cerebral edema at SVC
rossclamping.10 Anesthesists should be familiar with this
roblem to reduce the risk of neurologic consequences or
2) had a lower 5-year survival rate compared with that
0.13).es (N
p arly postoperative ARDS.
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G
TSOnce adequate standard of care is estabilished, maximum
ttention should be placed on properly selecting patients
ost likely to benefit from extended pneumonectomy. As
reviously reported, the most important predictor is medi-
stinal nodal status,16,17 the impact of which was suggested
ut not statistically confirmed in our study because of the
mall dimension of the population. Patients with persistent
ediastinal nodal involvement after chemotherapy have a
oor long-term prognosis and should not be considered as
andidates for extended pneumonectomy. Given the fact
hat these tumors are close to the mediastinum, the PET scan
s rarely useful for preoperative detection of N2 disease.
onsequentially, mediastinoscopy should play a central role
n preoperative staging. The best strategy for restaging after
hemotherapy remains an open question.
Another debateble argument is the use of preoperative
hemotherapy in patients requiring extended surgery. Even
n the absence of concrete evidence from literature, we
dvocate the use of chemotherapy in T4 lung tumors for
our main reasons. The first is the clinical observation that
significant proportion of patients who undergo extended
urgery develop distant metastases that had not been evident
t preoperative staging, after surgery. The second reason is
he theoretical advantage of induction treatment (decreasing
umor size, increasing the likelihood of negative margin,
terilizing micro-metastatic disease, defining tumor re-
ponse to chemotherapy), which may facilitate surgery and
xclude patients with rapidly evolving disease. The third
onsideration is that a negative impact of induction chemo-
herapy on postoperative mortality has not been clearly
emonstrated. Finally, the benefits of chemotherapy in
erms of survival have been demonstrated in early stage,18
tage IIIa,19,20 and in stage IV.21 Why should T4 tumors
epresent an exception? The supposed survival advantage of
nduction chemotherapy was not evident in our series, and it
as instead due to the bias of selection and to the limited
imension of the population. Only a prospective random-
zed trial could confirm the actual advantages provided by
reoperative induction treatment. Unfortunately, its feasi-
ility is limited by several factors, the first being the diffi-
ulty of precise clinical staging in T4 tumors.
In our experience, 60-day postoperative mortality after
xtended pneumonectomy is in the order of 10%, doubled as
ompared with that of standard pneumonectomy.22 This
ncreased mortality rate is due to a higher rate of surgical
nd respiratory complications. In terms of surgical compli-
ations, the most dramatically negative event remains bron-
hopleural fistula, particularly in the case of carinal resec-
ion, because no effective salvage repair procedure exists.
he increase of respiratory complications is probably linked
o preoperative chemotherapy by the mean of Dlco impaire-
ent.23 It is advisable that all candidates for extendedneumonectomy are submitted to Dlco assessment before
270 The Journal of Thoracic and Cardiovascular Surgery ● Novnd after chemotherapy, because patients with a Dlco loss
0% are probably at higher risk.
From an ethical point of view, is it acceptable to propose a
rocedure with a 10% postoperative mortality rate? It depends
n the alternative, which is chemoradiotherapy with curative
ntent. Five-year survival after chemoradiotherapy in stage III
SCLC is 3–10%.24 Our reported surgical survival, compris-
ng R patients, was 22%. There is no mean to define whether
urgical treatment translates into better cure, but patients are
iven a chance of permanent cure, which is exceptional by the
ean of the other treatment. This is what patients and surgeons
ant.
This study is limited by 3 factors: its retrospective de-
ign, the small number of cases, and the combination of T3
chest wall and diaphragm) and T4 tumors. The first factor
s common to all the other published studies, and it is
robably counterbalanced by the fact that our series was
ollected over a relatively short period of time. Concerning
he limited number of patients, as far as we know there are
ew studies published that focus on the combination of
extended” procedures and pneumonectomy,25 regardless of
he type of extended procedure. As such, we believe that the
nformation available from this series could be useful for
urther studies. Finally, the decision to consider chest wall
r diaphragmatic resections as extended procedures was
rbitrary but justified by their morbidity when associated
ith pneumonectomy. Two of the 4 patients who died
ithin 60 days after surgery underwent such a type of
rocedure.
In conclusion, “extended” pneumonectomy is a feasible
rocedure with an acceptable risk. To facilitate an accurate
election of patients, all candidates should undergo preop-
rative mediastinoscopy (excluding from surgery patients
ith mediastinal nodal metastases) and induction chemo-
herapy. In patients with response to chemotherapy, or with
table disease, extended pneumonectomy may afford a rad-
cal resection in more than 80% of cases and may result in
ermanent cure.
The Authors would like to thank Ms Kendall Katze for revising
he English form of the manuscript.
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iscussion
r Wood. Dr. Veronesi, congratulations on very good work by
ou and your group on a complex group of patients. These are
ifficult patients, and you certainly got good results both in oper-
tive outcomes as well as in survival in a group of patients with
dvanced disease.
I wanted to emphasize a couple of points that were more in
our paper than in the presentation. One was this aspect of clinical
verstaging of T4 disease. In your series you found it 15% of the
ime. There is a series from about four years ago in the European
ournal of Cardiothoracic Surgery that found clinical overstaging
f T4 disease 40% of the time. I think that it is important to
mphasize this experience since often a thoracic surgeon will not
ee these patients because they are clinically staged as T4 and felt
o be unresectable. Or we may see them and deny surgical con-
ideration for the same reason, yet they may really have T2-3
isease due to overstaging. This is one important aspect of looking
t patients with locally advanced disease.
My first question is whether you think there really is a differ-
nce between T3 and T4 disease. You said that was a limitation of
our study, but is there biologically any reason that there is a
ifference between T3 disease and T4 disease, and should we treat
hem any differently if we can achieve a complete resection?
Dr Veronesi. When I say limitation of the study, I mean that
he group of chest wall resection and diaphragm resection doesn’t
each the common definition of extended resections in literature
efinition. Nevertheless, I put this kind of patient in the work
ecause we found that after pneumonectomy they also have a high
ate of complications, so I think very aggressive surgery even in
his case is T3 and T4, T3 diaphragm or chest wall. We included
t for this reason, but the biologic difference I think is not so high,
ecause in both cases I suggest induction chemotherapy. It may be
hat downstaging after chemotherapy may make a T4 become a T3
fter surgical exploration.
Dr Wood. This is another place where we can educate our
edical colleagues that we work with because they often consider
4 to be a contraindication to surgery and biologically the differ-
ntiation is arbitrary. It is arbitrary, based upon a historical surgical
efinition of what we can resect or not, and that is changing.
Your conclusions emphasized the importance of mediastinal
taging and I couldn’t agree with you more. The principles of
uccess in lung cancer surgery are completeness of resection,
hich is more difficult in this group of patients, and nodal status.
t does appear that if these patients also have advanced nodal status
hen they probably are not going to benefit from surgery. I agree
ompletely with you in that regard.
I would respectfully disagree with you about the role of induc-
ion chemotherapy. Most of your patients had induction chemo-
herapy, which prevents you from being able to really compare the
mpact of not having induction chemotherapy or having it. The
urported benefits are trying to decrease the extent of resection or
mprove resectability with negative margins and to treat potential
ystemic disease. These patients do need systemic therapy at some
oint in their treatment but not necessarily before surgery. Che-
otherapy does create the problem of figuring out where the
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TSargins should be because of the chemotherapy response around
umor. You also made the point that induction therapy increases
orbidity and mortality in pneumonectomy, so I guess I would
hallenge you and question: do you really think that we should
ive these patients chemotherapy? We do not have strong evidence
hat it increases resectability. We do have strong evidence that it
ncreases morbidity and mortality. Should we reconsider this con-
lusion from your paper?
Dr Veronesi. In another work we are going to publish, we
ound that induction chemotherapy increased morbidity but finally
ot mortality in pneumonectomy, so we had more than 50 pneu-
onectomies after chemotherapy. The other observation I can
ake is the few long-term survivals in this series had all received
nduction chemotherapy. I know that it is not significant from a
tatistical point of view but it is an observation.
Dr Wood. Yes, but all but nine of your patients had induction
hemotherapy, so it would be hard for it to be otherwise.
Dr Veronesi. The fact that . . . (end of cassette)
Dr Wood. We recommend mediastinoscopy in all of these
atients, not only for identifying nodal disease, but also for min-
mally invasive exploration of the mediastinum. Mediastinoscopy
an help determine the extent of airway involvement or the extent
f pulmonary artery involvement before committing the patient to
thoracotomy, as well as developing some of the tissue planes that
re subsequently useful when you are doing a carinal resection.
re you doing mediastinoscopy at the time of the planned resec-
ion and do you find that same benefit in terms of staging the
ediastinum not just for nodes but for extent of primary tumor?
Dr Veronesi. Not particularly. We use it mostly for nodal
taging and when not positive we perform induction chemotherapy
nd then we don’t perform a redo-mediastinoscopy, so usually it is
long period in advance compared with the surgery.
Dr Wood. Congratulations again on your work. Very nice
resentation and nice paper. Thank you.
Dr Veronesi. Thank you.
Doctor [unidentified]. Thank you so much for giving me the
pportunity to raise some questions. It was a fine presentation, but
or me there remain three questions. The first one, you mentioned
he combination of T3 and T4 patients is a weak point of your
resentation. Why didn’t you exclude T3 patients who have, as we
272 The Journal of Thoracic and Cardiovascular Surgery ● Novll know, the much better prognosis? The second question is, you
entioned four T1 cases. How _____ to explain? And the third
ne, there begins really the atrial resection: all intrapericardial
esections or where is exactly the border?
Dr Veronesi. I’ll start with your final question. The resection
as defined as resection not of the vein but of the wall of the
trium at the pathologic exam, so the muscle layer was present. I
ouldn’t understand your second question, sorry. Could you repeat
t?
Doctor [unidentified]. The second question is, you made a
able with 4 cases in stage T1.
Dr Veronesi. One case. There was 1 case of stage T1.
Doctor [unidentified]. Why do you do an extended pneumo-
ectomy for T1?
Dr Veronesi. It was a case that had a major response to
hemotherapy, so we couldn’t know the tissue viability before the
urgery.
And the first question about T3 and T4, we discussed before
ith Dr. Wood.
Doctor [unidentified]. Yes, but T3 is quite another entity from
4. If you mix it, you ameliorate the prognosis of the patients of
he _____ group. I don’t know whether it is correct or not.
Dr Veronesi. Yes, but maybe some T3 were T4 before induc-
ion chemotherapy, so we never know that.
Dr Doty. I was taken by the sentence in the abstract, “Neither
ostoperative outcome nor survival were significantly influenced
y the type of extended pneumonectomy.” Just to give you a little
erspective on this, my first experience over 40 years ago with the
neumonectomy was with the late George Lindesmith, and it was
large bronchogenic carcinoma originating in the right main
ronchus deep in the mediastinum. I was really determined to have
he opportunity to resect that lung, and George Lindesmith said to
e, “You know, Don, getting out a lung cancer is always possible.
t just depends on how hard you want to work, but it won’t make
ny difference in the end.” And so here we are with 23% survival
n extended pneumonectomies 40 years later. It’s kind of the same,
sn’t it? I mean have we really made any progress on this? I just
eave you to answer that question. You don’t have to. You’re too
oung.Dr Mulligan. Perhaps a question for the group to reflect upon.
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